These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Should all children with suspected or confirmed malignant hyperthermia susceptibility be admitted after surgery? A 10-year review. Yentis SM; Levine MF; Hartley EJ Anesth Analg; 1992 Sep; 75(3):345-50. PubMed ID: 1510254 [TBL] [Abstract][Full Text] [Related]
3. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests]. Mortier W; Breucking E Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201 [TBL] [Abstract][Full Text] [Related]
4. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Hackl W; Winkler M; Mauritz W; Sporn P; Steinbereithner K Br J Anaesth; 1991 Jan; 66(1):138-40. PubMed ID: 1997050 [TBL] [Abstract][Full Text] [Related]
5. Effect of propofol on the malignant hyperthermia susceptible pig model. Krivosic-Horber R; Reyfort H; Becq MC; Adnet P Br J Anaesth; 1989 Jun; 62(6):691-3. PubMed ID: 2787665 [TBL] [Abstract][Full Text] [Related]
6. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627 [TBL] [Abstract][Full Text] [Related]
7. Screening test for malignant hyperthermia in patients with persistent hyperCKemia: a pilot study. Johannsen S; Berberich C; Metterlein T; Roth C; Reiners K; Roewer N; Schuster F Muscle Nerve; 2013 May; 47(5):677-81. PubMed ID: 23400941 [TBL] [Abstract][Full Text] [Related]
8. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863 [TBL] [Abstract][Full Text] [Related]
9. Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs. Hackl W; Mauritz W; Schemper M; Winkler M; Sporn P; Steinbereithner K Br J Anaesth; 1990 Apr; 64(4):425-9. PubMed ID: 2334615 [TBL] [Abstract][Full Text] [Related]
10. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia? Ellis FR; Halsall PJ; Hopkins PM Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078 [TBL] [Abstract][Full Text] [Related]
11. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Mezin P; Payen JF; Bosson JL; Brambilla E; Stieglitz P Br J Anaesth; 1997 Sep; 79(3):327-31. PubMed ID: 9389850 [TBL] [Abstract][Full Text] [Related]
12. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Wappler F; Scholz J; Köchling A; Steinfath M; Krause T; Schulte am Esch J Br J Anaesth; 1997 May; 78(5):541-7. PubMed ID: 9175969 [TBL] [Abstract][Full Text] [Related]
14. Use of vecuronium and doxapram in patients susceptible to malignant hyperthermia. Ording H; Fonsmark L Br J Anaesth; 1988 Mar; 60(4):445-9. PubMed ID: 2895665 [TBL] [Abstract][Full Text] [Related]
16. [Incidence of disposition for malignant hyperthermia in patients with neuromuscular diseases]. Wappler F; Scholz J; von Richthofen V; Fiege M; Köchling A; Matschke J; Winkler G; Schulte am Esch J Anasthesiol Intensivmed Notfallmed Schmerzther; 1998 Jun; 33(6):373-80. PubMed ID: 9689395 [TBL] [Abstract][Full Text] [Related]
17. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory. Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of spin resonance spectroscopy of red blood cell membranes to detect malignant hyperthermia susceptibility. Halsall PJ; Ellis FR; Knowles PF Br J Anaesth; 1992 Nov; 69(5):471-3. PubMed ID: 1334685 [TBL] [Abstract][Full Text] [Related]
19. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle. Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Reyford HG; Adamantidis MM; Dupuis BA Can J Anaesth; 1990 Jul; 37(5):556-9. PubMed ID: 2372858 [TBL] [Abstract][Full Text] [Related]
20. Muscular body build and male sex are independently associated with malignant hyperthermia susceptibility. Butala B; Brandom B Can J Anaesth; 2017 Apr; 64(4):396-401. PubMed ID: 28063098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]